- Home
- AOSL vs OCS Comparison
AOSL vs OCS Comparison
Compare AOSL & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOSL
- OCS
- Stock Information
- Founded
- AOSL 2000
- OCS 2003
- Country
- AOSL United States
- OCS Switzerland
- Employees
- AOSL N/A
- OCS N/A
- Industry
- AOSL Semiconductors
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AOSL Technology
- OCS Health Care
- Exchange
- AOSL Nasdaq
- OCS Nasdaq
- Market Cap
- AOSL 768.5M
- OCS 689.8M
- IPO Year
- AOSL 2010
- OCS N/A
- Fundamental
- Price
- AOSL $17.34
- OCS $18.27
- Analyst Decision
- AOSL Buy
- OCS Strong Buy
- Analyst Count
- AOSL 3
- OCS 4
- Target Price
- AOSL $35.67
- OCS $30.25
- AVG Volume (30 Days)
- AOSL 580.7K
- OCS 48.2K
- Earning Date
- AOSL 05-07-2025
- OCS 05-07-2025
- Dividend Yield
- AOSL N/A
- OCS N/A
- EPS Growth
- AOSL N/A
- OCS N/A
- EPS
- AOSL N/A
- OCS N/A
- Revenue
- AOSL $666,399,000.00
- OCS $757,024.00
- Revenue This Year
- AOSL $5.32
- OCS $57.00
- Revenue Next Year
- AOSL $6.62
- OCS $1,820.89
- P/E Ratio
- AOSL N/A
- OCS N/A
- Revenue Growth
- AOSL 4.12
- OCS N/A
- 52 Week Low
- AOSL $16.38
- OCS $10.79
- 52 Week High
- AOSL $53.29
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AOSL 33.14
- OCS 52.53
- Support Level
- AOSL $17.16
- OCS $14.00
- Resistance Level
- AOSL $20.31
- OCS $16.39
- Average True Range (ATR)
- AOSL 2.37
- OCS 0.94
- MACD
- AOSL -0.16
- OCS 0.22
- Stochastic Oscillator
- AOSL 9.87
- OCS 71.40
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.